# Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

> **NCT00038402** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 74 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Herceptin
- **DRUG:** Taxol
- **DRUG:** Fluorouracil
- **DRUG:** Cytoxan
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT00038402
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2004-11
- **Final completion:** 2011-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2012-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038402, "Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00038402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*